Aged care provider Anglicare has hit back at a class action filed on behalf of 25 people whose loved ones died during a COVID-19 outbreak at the Newmarch House in Sydney, saying it owed no duty of care to prevent mental harm to its residents’ family members.
A Sanofi unit has lost its bid for more time to file a divisional application in relation to a hemophilia treatment, with an IP Australia delegate finding that a US lawyer’s mistaken belief about Australian patent law did not explain the company’s failure to make the application in time.
The High Court has agreed to weigh in on a 16-year battle between the federal government and French drug maker Sanofi-Aventis over an allegedly unjustified court order that prevented the release of a generic version of blockbuster blood-thinner Plavix.
Despite proposing a divestiture as part of its planned takeover of Healius, Australian Clinical Labs has failed to win the approval of the competition regulator for the $1.5 billion deal.
A judge has told the law firm that has taken over a class action against Philips Electronics over recalled sleep apnea machines to take its time when amending the pleading, which he said was not the “finest piece of work” he’d ever seen.
‘Serious and systemic’ failures in Australian Clinical Labs’ cyber framework left the pathology services provider vulnerable to a cyberattack that exposed the sensitive health data of more than 223,000 people, including tests for fertility and sexually transmitted diseases, according to the OAIC.
A judge has signed off on almost $7.5 million in fees billed by the law firm behind the pelvic mesh class action against Boston Scientific, eight months after he approved the device maker’s $105 million settlement.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
A judge has upheld a ruling that rejected a bid by two class actions against Victorian aged care providers for insurance and financial information, finding the court likely does not have the power to order the production of documents that are not relevant to the proceeding.
South Korean biosimilars company Samsung Bioepis has sued to invalidate two patents held by a German competitor for a pre-filled syringe to treat age-related eye diseases, as generic drug makers race for a piece of the lucrative eye drug market.